REGULATION OF MYOMETRIAL RELAXATION: AGONIST-SPECIFIC cGMP ACTION
子宫肌层松弛的调节:激动剂特异性 cGMP 作用
基本信息
- 批准号:8044194
- 负责人:
- 金额:$ 23.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-03-05 至 2013-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAlternative SplicingBindingBiochemicalBiologicalCalciumCaveolaeCaviaCell membraneCellsCholesterolCyclodextrinsDeciduaDetergentsDevelopmentEnzymesEquilibriumFailureFamilyGlobal ChangeGlycolipidsGoalsGuanosineGuanylate CyclaseHormonalHumanInterphase CellIsoenzymesLeadLeucine ZippersLipidsMeasuresMembraneMethodsMolecularMolecular TargetMuscleMuscle CellsMyometrialMyosin ATPaseNatureNitric OxideParticulatePathway interactionsPeptidesPhosphoric Monoester HydrolasesPhosphorylationPhysiologicalPregnancyPremature LaborProcessProtein BindingProtein IsoformsProteinsRegulationRelaxationResearchResearch ProposalsSarcoplasmic ReticulumSignal PathwaySignal TransductionSmooth MuscleSmooth Muscle MyocytesSoluble Guanylate CyclaseTherapeuticTimeTissuesTocolytic AgentsUterine ContractionUterine GlandUterusWomancGMP-dependent protein kinase Ibetadesignfetalguanylinindium arsenidemyometriummyosin phosphatasenew therapeutic targetparacrinepregnantprematurepreventreceptorresearch studyresponsetherapeutic targettooluptakeuroguanylin
项目摘要
DESCRIPTION (provided by applicant): Our research objective is to determine the signal transduction mechanisms that are unique to, or altered in the human myometrium in preterm labor because this is presently unknown and because current treatments for premature labor (PTL) are wholly inadequate. No matter the varied causes of PTL (fetal or maternal) in any given woman, in unexplained cases, changes will inevitably be found in myometrial signaling pathways or the timing of their activation/inactivation. We will take experimental approaches in human and guinea pig myometrial cells and tissues that will converge in an understanding of the smooth muscle mechanisms of prematurity and provide one or more therapeutic targets not previously known. Because myometrial quiescence is independent of nitric oxide induced global elevations of cGMP; while the peptide activator of particulate guanylyl cyclase (pGC-Type C) relaxes the myometrium in a cGMP-dependent fashion, we suggest that a conundrum exists in our current understanding of cGMP action in myometrial smooth muscle. We will investigate the hypothesis that the cGMP elevation following activation of pGC exists and acts in a compartment distinct from that of soluble guanylyl cyclase. We propose that myometrial pGC is compartmented to myocyte caveolae and/or lipid-rich membrane rafts and, together with the known ability of PKG to increase the uptake of calcium into sarcoplasmic reticulum, acts via PKG Type II to activate a myosin phosphatase (MP) isozyme containing a leucine zipper that permits its activation by PKGII. This in turn lowers the phosphorylation of the rMLC and thus promotes relaxation of uterine muscle. Relaxation of the myometrium by activators of soluble guanylyl cyclase, while leading to the accumulation of cGMP, does so in a soluble compartment that is not in equilibrium with the lipid-rich signaling domain and does not lead to activation of MP despite activation of PKGI. We propose that cGMP in the soluble compartment of the cell acting via PKGI does not regulate relaxation of myometrial smooth muscle. Exploring our hypotheses in uterine smooth muscle with physiological, biochemical and molecular methods will further our understanding of the regulation of myometrial quiescence. Discovery of the precise and unique nature of myometrial signaling will lead to a better understanding of the regulation of labor and preterm labor and may lead to new therapeutic targets in PTL.
描述(由申请人提供):我们的研究目标是确定早产中人类子宫肌层特有或改变的信号转导机制,因为目前尚不清楚,而且目前对早产(PTL)的治疗完全不够。无论任何女性 PTL(胎儿或母体)的原因多种多样,在无法解释的情况下,子宫肌层信号通路或其激活/失活时间都不可避免地会发生变化。我们将在人类和豚鼠的子宫肌层细胞和组织中采取实验方法,这些方法将集中于对早产儿平滑肌机制的理解,并提供一种或多种以前未知的治疗靶点。因为子宫肌层静止与一氧化氮诱导的 cGMP 整体升高无关;虽然颗粒鸟苷酸环化酶(pGC-C 型)的肽激活剂以 cGMP 依赖性方式松弛子宫肌层,但我们认为,我们目前对子宫肌层平滑肌中 cGMP 作用的理解存在一个难题。我们将研究以下假设:pGC 激活后 cGMP 升高存在,并在与可溶性鸟苷酸环化酶不同的区室中发挥作用。我们认为,子宫肌层 pGC 被划分为肌细胞小凹和/或富含脂质的膜筏,并且与已知的 PKG 增加肌浆网钙吸收的能力一起,通过 PKG II 型发挥作用,激活含有亮氨酸拉链的肌球蛋白磷酸酶 (MP) 同工酶,使其通过以下方式激活: PKGII。这反过来又降低了 rMLC 的磷酸化,从而促进子宫肌肉松弛。可溶性鸟苷酸环化酶激活剂使子宫肌层松弛,同时导致 cGMP 积累,但这是在可溶性区室中进行的,该区室与富含脂质的信号结构域不平衡,并且尽管 PKGI 激活,但不会导致 MP 激活。我们认为,细胞可溶性区室中的 cGMP 通过 PKGI 起作用,并不调节子宫肌层平滑肌的松弛。用生理、生化和分子方法探索子宫平滑肌的假设将进一步加深我们对子宫肌层静止调节的理解。发现子宫肌层信号传导的精确和独特性质将有助于更好地了解分娩和早产的调节,并可能导致 PTL 的新治疗靶点。
项目成果
期刊论文数量(14)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A role for nucleotides in support of breast cancer angiogenesis: heterologous receptor signalling.
- DOI:10.1038/bjc.2011.134
- 发表时间:2011-05-10
- 期刊:
- 影响因子:8.8
- 作者:Yokdang, N.;Tellez, J. D.;Tian, H.;Norvell, J.;Barsky, S. H.;Valencik, M.;Buxton, I. L. O.
- 通讯作者:Buxton, I. L. O.
Extracellular NM23 Signaling in Breast Cancer: Incommodus Verum.
- DOI:10.3390/cancers3032844
- 发表时间:2011-09
- 期刊:
- 影响因子:5.2
- 作者:Buxton IL;Yokdang N
- 通讯作者:Yokdang N
Validation of the CSI health station 6K blood pressure kiosk.
CSI 健康站 6K 血压亭的验证。
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Buxton,IainLO;Adams,JohnQ;Gore,Mark;Sullivan,CharlesR
- 通讯作者:Sullivan,CharlesR
LC/MS/MS data analysis of the human uterine smooth muscle S-nitrosoproteome fingerprint in pregnancy, labor, and preterm labor.
- DOI:10.1016/j.dib.2015.07.031
- 发表时间:2015-09
- 期刊:
- 影响因子:1.2
- 作者:Ulrich CC;Quilici DR;Schlauch KA;Burkin HR;Buxton IL
- 通讯作者:Buxton IL
Hiding in Plain Sight: Nebivolol Exhibits Compelling Tocolytic Properties.
- DOI:10.1111/jcmm.13883
- 发表时间:2018-12
- 期刊:
- 影响因子:5.3
- 作者:Barnett SD;Buxton ILO
- 通讯作者:Buxton ILO
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
IAIN L BUXTON其他文献
IAIN L BUXTON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('IAIN L BUXTON', 18)}}的其他基金
Post-translational Modification of Cx43 Regulates Myometrial Quiescence
Cx43 的翻译后修饰调节子宫肌层静止
- 批准号:
10575364 - 财政年份:2023
- 资助金额:
$ 23.85万 - 项目类别:
Regulation of CAP Protein S-Nitrosation in Preterm Labor
早产中 CAP 蛋白 S-亚硝化的调节
- 批准号:
10221011 - 财政年份:2018
- 资助金额:
$ 23.85万 - 项目类别:
Regulation of CAP Protein S-Nitrosation in Preterm Labor
早产中 CAP 蛋白 S-亚硝化的调节
- 批准号:
10002335 - 财政年份:2018
- 资助金额:
$ 23.85万 - 项目类别:
REGULATION OF MYOMETRIAL RELAXATION: AGONIST-SPECIFIC cGMP ACTION
子宫肌层松弛的调节:激动剂特异性 cGMP 作用
- 批准号:
8138103 - 财政年份:2010
- 资助金额:
$ 23.85万 - 项目类别:
REGULATION OF MYOMETRIAL RELAXATION: AGONIST-SPECIFIC cGMP ACTION
子宫肌层松弛的调节:激动剂特异性 cGMP 作用
- 批准号:
7599726 - 财政年份:2007
- 资助金额:
$ 23.85万 - 项目类别:
REGULATION OF MYOMETRIAL RELAXATION: AGONIST-SPECIFIC cGMP ACTION
子宫肌层松弛的调节:激动剂特异性 cGMP 作用
- 批准号:
7781360 - 财政年份:2007
- 资助金额:
$ 23.85万 - 项目类别:
REGULATION OF MYOMETRIAL RELAXATION: AGONIST-SPECIFIC cGMP ACTION
子宫肌层松弛的调节:激动剂特异性 cGMP 作用
- 批准号:
7201882 - 财政年份:2007
- 资助金额:
$ 23.85万 - 项目类别:
REGULATION OF MYOMETRIAL RELAXATION: AGONIST-SPECIFIC cGMP ACTION
子宫肌层松弛的调节:激动剂特异性 cGMP 作用
- 批准号:
7369765 - 财政年份:2007
- 资助金额:
$ 23.85万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 23.85万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 23.85万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 23.85万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 23.85万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 23.85万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 23.85万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 23.85万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 23.85万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 23.85万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 23.85万 - 项目类别:














{{item.name}}会员




